🔗 Share this article

While America continues making historic revisions to its vaccine schedules, an unexpected name has emerged in a surprising turn: Høeg, an American of Danish descent sports physician and public health researcher who first made her name by questioning coronavirus shots during the global health crisis and has zeroed in on potential deaths after COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Childhood Vaccine Program

Agency leaders planned to reveal major revisions to the pediatric vaccine schedule earlier this month, aligning the US with the Danish immunization schedule, according to reports – a significant shift that would put the US at odds with much of the international standard with little proof for benefit. The planned update has been delayed until the coming year.

Rather than the top vaccines chief, Høeg is listed to speak at the event. She was newly appointed acting director of the FDA’s CDER, the fifth individual to head the division this calendar year.

A New Direction at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and biologics divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it signals a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for halting some pediatric immunization guidelines in the US to become more like the Danish model, a nation with nationalized medicine and a population about the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccines – typically the purview of Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Background

Dr. Høeg has no apparent track record in drug development, oversight or leadership, which has been customary for former leaders of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since March.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in managing a major agency. She lacks background in industry regulation.”

Former commissioners of CBER would “grasp regulatory frameworks and the underlying principles of drug development”, noted Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who headed the center have had.”

This division has an enormous portfolio at the agency, Woodcock pointed out.

“Many people just focuses on the novel medication approvals, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and all of those need to be managed,” Dr. Woodcock noted. “The thing you neglect, that is the part that I always told people is going to bite you.”

There is also, a significant leadership element to the position, which manages over 5,000 staff members. “It’s a enormous administrative position, if you do it right,” the former official concluded.

Official Statement and Disputed Initiatives

Regarding concerns about Dr. Høeg's credentials and whether this appointment signifies more teamwork among FDA leaders on immunizations, a spokesperson responded that the “concerns rely on incorrect assumptions”.

“Her resume matches the responsibilities of her role,” the representative stated, citing the period Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's recently launched fast-track approval initiative, a controversial rapid therapy clearance system that apparently troubled her preceding directors. “By what process are these drugs being selected for this expedited pathway? Who takes the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the FDA right now.”

Overall, he stated, “the agency looks to be trending towards more relaxed oversight of most medications, aside from immunizations.”

Established Track Record on Immunizations

With immunizations, Høeg has a clearer, if problematic, history, Howard said. She published a research paper using non-validated volunteer-provided data to assess the incidence of myocarditis after Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are riskier than they are.

Part of her “wish list” for the current government encompassed revising regulations for new vaccines and halting “unnecessary” immunizations, she said following the vote on a audio program. At the agency, Høeg has according to sources floated the idea of excluding adolescent males from getting Covid vaccines.

“She is an all-around dogmatist who starts off with her conclusions and tailors the evidence to fit the science in a extremely misleading, dishonest manner,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|